Distinguishing anemia and iron deficiency of heart failure: Signal for severity of disease or unmet therapeutic need?

Pharmacotherapy

Volumn 34, Issue 7, 2014, Pages 719-732

  Beavers, Craig J ^a   Alburikan, Khalid A ^b   Rodgers, Jo E ^b   Dunn, Steven P ^c   Reed, Brent N ^d  

^a CENTENNIAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

anemia; cardiology; erythropoietin stimulating agents; heart failure; iron deficiency; iron supplementation; transfusion

Indexed keywords

ASCORBIC ACID; CYANOCOBALAMIN; FERRIC CARBOXYMALTOSE; FERRITIN; FOLIC ACID; HEMOGLOBIN; IRON; IRON SACCHARATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ANEMIA; ARTICLE; BLOOD SMEAR; BLOOD TRANSFUSION; BONE MARROW BIOPSY; DIETARY INTAKE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MECHANISM; EDEMA; EXERCISE TOLERANCE; GASTROINTESTINAL EDEMA; HEART FAILURE; HUMAN; INFLAMMATION; INTESTINE PERFUSION; IRON ABSORPTION; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON THERAPY; KIDNEY FAILURE; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK BENEFIT ANALYSIS; SYMPTOMATOLOGY; ANEMIA, IRON-DEFICIENCY; ANIMAL; BLOOD; HEALTH SERVICE; SEVERITY OF ILLNESS INDEX; TRENDS;

ANEMIA; ANEMIA, IRON-DEFICIENCY; ANIMALS; DIAGNOSIS, DIFFERENTIAL; HEALTH SERVICES NEEDS AND DEMAND; HEART FAILURE; HUMANS; IRON; SEVERITY OF ILLNESS INDEX;

EID: 84903846546     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1412     Document Type: Article

References (53)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013; 127: e6-245.
2. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. [Internet]. World Health Organization, 2011. Available from http://www.who.int/vmnis/indicators/haemoglobin. pdf. Accessed October 23, 2013.
3. Tang WHW, Yeo PSD,. Epidemiology of anemia in heart failure. Heart Fail Clin 2010; 6: 271-8.
4. Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008; 52: 818-27.
5. Adams KF Jr, Patterson JH, Oren RM, et al. Prospective assessment of the occurrence of anemia in patients with heart failure: results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry. Am Heart J 2009; 157: 926-32.
6. Gunawardena S, Dunlap ME,. Anemia and iron deficiency in heart failure. Curr Heart Fail Rep 2012; 9: 319-27.
7. Shah R, Agarwal AK,. Anemia associated with chronic heart failure: current concepts. Clin Interv Aging 2013; 8: 111-22.
8. Tang WHW, Tong W, Jain A, Francis GS, Harris CM, Young JB,. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol 2008; 51: 569-76.
9. Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006; 48: 2485-9.
10. Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P,. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 2013; 34: 816-29.
11. Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008; 51 (2): 103-12.
12. Anker SD, Comin Colet J, Filippatos G, et al. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361(25): 2436-48.
13. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010; 31: 1872-80.
14. Ezekowitz JA, McAlister FA, Armstrong PW,. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003; 107: 223-5.
15. Tang Y-D, Katz SD,. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006; 113: 2454-61.
16. He S-W, Wang L-X,. The impact of anemia on the prognosis of chronic heart failure: a meta-analysis and systemic review. Congest Heart Fail 2009; 15: 123-30.
17. Mak G, Murphy NF, McDonald K,. Anemia in heart failure: to treat or not to treat? Curr Treat Options Cardiovasc Med 2008; 10: 455-64.
18. Silverberg DS, Wexler D, Iaina A, Schwartz D,. The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions. Clin Exp Nephrol 2009; 13: 101-6.
19. Felker GM, Gattis WA, Leimberger JD, et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol 2003; 92: 625-8.
20. Young JB, Abraham WT, Albert NM, et al. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol 2008; 101: 223-30.
21. Kosiborod M, Curtis JP, Wang Y, et al. Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project. Arch Intern Med 2005; 165: 2237-44.
22. Varma A, Appleton DL, Nusca A, et al. Iron deficiency anemia and cardiac mortality in patients with left ventricular systolic dysfunction undergoing coronary stenting. Minerva Cardioangiol 2010; 58: 1-10.
23. Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005; 26: 2232-7.
24. Felker GM, Adams KF Jr, Gattis WA, O'Connor CM,. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol 2004; 44: 959-66.
25. Androne A-S, Katz SD, Lund L, et al. Hemodilution is common in patients with advanced heart failure. Circulation 2003; 107: 226-9.
26. Ishani A, Weinhandl E, Zhao Z, et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2005; 45: 391-9.
27. Mast AE, Blinder MA, Gronowski AM, Chumley C, Scott MG,. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem 1998; 44: 45-51.
28. Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010; 16: e1-194.
29. Hallberg L, Brune M, Rossander L,. Effect of ascorbic acid on iron absorption from different types of meals. Studies with ascorbic-acid-rich foods and synthetic ascorbic acid given in different amounts with different meals. Hum Nutr Appl Nutr 1986; 40: 97-113.
30. Palazzuoli A, Silverberg D, Iovine F, et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006; 152: 1096.e9-15.
31. Beck-da-Silva L, Piardi D, Soder S, et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol 2013; 168: 3439-42.
32. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J,. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21 (2): 378-82.
33. Danielson BG,. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004; 15 (Suppl. 2): 93-8.
34. Scheiber-Mojdehkar B, Lutzky B, Schaufler R, Sturm B, Goldenberg H,. Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation. J Am Soc Nephrol 2004; 15: 1648-55.
35. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37: 1775-80.
36. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003; 18: 141-6.
37. Bolger AP, Bartlett FR, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006; 48 (6): 1225-7.
38. Toblli JE, Lombraña A, Duarte P, Di Gennaro F,. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007; 50 (17): 1657-65.
39. Usmanov RI, Zueva EB, Silverberg DS, Shaked M,. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 2008; 21 (2): 236-42.
40. Ganzoni AM,. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr 1970; 100: 301-3.
41. Anker SD, Colet JC, Filippatos G, et al. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 2009; 11: 1084-91.
42. Cleland JGF, Sullivan JT, Ball S, et al. Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation. J Cardiovasc Pharmacol 2005; 46: 155-61.
43. Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007; 28: 2208-16.
44. Ngo K, Kotecha D, Walters JA, et al. Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev 2010: CD007613.
45. Kotecha D, Ngo K, Walters JAE, Manzano L, Palazzuoli A, Flather MD,. Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials. Am Heart J 2011; 161: 822-31.e2.
46. Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2007; 49: 753-62.
47. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne A-S,. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003; 21: 294-9.
48. Parissis JT, Kourea K, Panou F, et al. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J 2008; 155: 751.e1-7.
49. Palazzuoli A, Silverberg DS, Iovine F, et al. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 2007; 154: 645.e9-15.
50. Kourea K, Parissis JT, Farmakis D, et al. Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil 2008; 15: 365-9.
51. Ghali JK, Anand IS, Abraham WT, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008; 117: 526-35.
52. Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013; 368: 1210-9.
53. Qaseem A, Humphrey LL, Fitterman N, Starkey M, Shekelle P, Clinical Guidelines Committee of the American College of Physicians. Treatment of anemia in patients with heart disease: a clinical practice guideline from the American college of physicians. Ann Intern Med 2013; 159: 770-9.